British journal of cancer · 2026
Podoplanin-defined tumour plasticity and CCR7-mediated lymphatic metastasis in triple-negative breast cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Zhi, Ingebriktsen Lise Martine, Bekkhus Tove, Ma Lyusong, Queiro-Palou Antonio, Shi Wenyang, Bazioti Anastasia, Panagias Michail Angelos, Vigorelli Martina, Lehrstrand Joakim Harry, Ring Sarah, Dimberg Anna, Wik Elisabeth, Hoivik Erling Andre, Fuxe Jonas, Ulvmar Maria H
Аннотация
BACKGROUND: Lymphatic metastasis is strongly associated with poor prognosis. Although the chemokine receptor CCR7 is a well-established promoter of lymphatic dissemination, its prognostic relevance remains weak. We show that tumour cell plasticity, defined by podoplanin (PDPN)-expression and promoted by hypoxia, intersects with CCR7 function in triple-negative breast cancer (TNBC).
METHODS: In vivo and in vitro studies using a CCR7-expressing TNBC mouse model were combined with transcriptomic profiling. Human relevance was assessed using scRNA-seq datasets from cell lines and primary tumours, as well as METABRIC breast cancer cohorts.
RESULTS: A PDPN-defined tumour cell mesenchymal shift, promoted by hypoxia, was required for efficient CCR7-driven lymphatic metastasis and tumour progression. PDPN-expression was linked to tumour cell collagen-expression and suppression of interferon-signalling, features associated with an immune-cold microenvironment. PDPN-expression with effects on interferon and collagen programmes was observed across murine and human TNBC cell lines and correlated with hypoxia signatures in primary TNBC, mirroring murine findings. In METABRIC, a high combined CCR7-PDPN score predicted poor survival in lymph node-positive patients, whereas either marker alone lacked prognostic value.
CONCLUSIONS: PDPN is a tumour cell-associated biomarker of plasticity in TNBC, revealing synergy between hypoxia-induced mesenchymal phenotypic shifts and CCR7 in promoting lymphatic dissemination and poor prognosis.
METHODS: In vivo and in vitro studies using a CCR7-expressing TNBC mouse model were combined with transcriptomic profiling. Human relevance was assessed using scRNA-seq datasets from cell lines and primary tumours, as well as METABRIC breast cancer cohorts.
RESULTS: A PDPN-defined tumour cell mesenchymal shift, promoted by hypoxia, was required for efficient CCR7-driven lymphatic metastasis and tumour progression. PDPN-expression was linked to tumour cell collagen-expression and suppression of interferon-signalling, features associated with an immune-cold microenvironment. PDPN-expression with effects on interferon and collagen programmes was observed across murine and human TNBC cell lines and correlated with hypoxia signatures in primary TNBC, mirroring murine findings. In METABRIC, a high combined CCR7-PDPN score predicted poor survival in lymph node-positive patients, whereas either marker alone lacked prognostic value.
CONCLUSIONS: PDPN is a tumour cell-associated biomarker of plasticity in TNBC, revealing synergy between hypoxia-induced mesenchymal phenotypic shifts and CCR7 in promoting lymphatic dissemination and poor prognosis.